Lupin and Lilly partner for improved access to diabetes treatment in India

Lupin to market Aplevant®, Lilly's dulaglutide once-weekly injection for Type 2 diabetes

Mumbai, October 1, 2018: Pharma Major Lupin Limited (“Lupin”) and Eli Lilly and Company (India) Pvt. Ltd. (“Lilly India”), have announced the expansion of their business partnership aimed at widening access to innovative diabetes medicines in India. Under the new partnership, Lupin will distribute and market Lilly’s Aplevant® (dulaglutide), a once-weekly injection for type 2 diabetes treatment.

Aplevant® (dulaglutide) is a once-weekly injectable solution for adults with type 2 diabetes mellitus. Lupin expects to make Aplevant® available in India in October 2018.

This announcement builds on the Lupin and Lilly India business partnership initiated in 2011 to expand the promotion and distribution of Lilly’s diabetes portfolio in India where Lupin has a large network.

Rajeev Sibal, President – India Region Formulations, Lupin said, “Our long-standing partnership with Lilly has enabled us to emerge as a strong contender in the diabetes treatment arena. Lupin is the fastest growing company in the Indian diabetes market and is now ranked as the third largest company in the Anti-diabetes market in India on a MAT basis as of August 2018*. With this new partnership, we are expanding our diabetes portfolio to include a once-weekly diabetes treatment, and improving access to innovative medications for better diabetic care in India. We are delighted to partner with Lilly India and hope to continue building our product pipeline through strategic tie-ups for innovative healthcare solutions for patients and healthcare practitioners in India.”

Luca Visini, Managing Director, Lilly India said, “Lilly's heritage in diabetes spans from the first commercial release of insulin in 1923, to leading scientific discoveries of today. Since 1923, we have continuously strived to innovate to meet the diverse needs of people living with diabetes offering a wide portfolio of treatments among which include the first biosynthetic 'human' insulin with recombinant DNA technology, the first rapid insulin analog, and a once weekly non-insulin injection for type 2 diabetes. Building on this strong heritage and legacy in the diabetes field, and our commitment to make life better for all those living with diabetes in India, we are thrilled to work with Lupin to make our innovative therapies and solutions available to the large number of healthcare professionals and patients who need them.”

*IQVIA report - MAT August 2018 data.

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 8th largest generics pharmaceutical company both in terms of market capitalization (30th June 2018, Bloomberg) and revenues (31st March 2018, Bloomberg LTM) globally. The Company is the 4th largest pharmaceutical player in the US by prescriptions (IQVIA MAT June 2018); 3rd largest Indian pharmaceutical company by global revenues (31st March 2018, Bloomberg LTM); 6 th largest generic pharmaceutical player in Japan and 5th largest company in the Indian Pharmaceutical Market (IQVIA MAT June 2018).

For the financial year ended 31st March, 2018, Lupin’s Consolidated sales and Net profits before exceptional items were at Rs. 155,598 million (USD 2.41 billion) and Rs. 13,934 million (USD 216 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on Twitter – www.twitter.com/lupinglobal

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

About Eli Lilly and Company

Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com.

Lilly has been a global leader in diabetes care since 1923, when we introduced the world’s first commercial insulin. Today, we are building upon this heritage by working to meet the diverse needs of people with diabetes and those who care for them. Through research and collaboration, a wide range of therapies, and a continued determination to provide real solutions—from medicines to support programs and more—we strive to make life better for all those affected by diabetes around the world. For more information, visit www.lillydiabetes.com.

About Eli Lilly India

Eli Lilly and Company (India) Pvt. Ltd. (Lilly), headquartered in Gurgaon, is a wholly owned subsidiary of Eli Lilly and Company, a global biopharmaceutical company headquartered in Indianapolis, USA. Eli Lilly (India) Pvt. Ltd. is marking its 25 year of presence in India this year. Eli Lilly India portfolio includes therapies for diabetes, lung cancer, gastric cancer, osteoporosis, men’s health and growth-hormone deficiency. To learn more about Lilly India, please visit https://www.lillyindia.co.in ; Facebook

Registered Office: Eli Lilly and Company (India) Pvt. Ltd., Plot# 92, Sector 32, Institutional Area, Gurgaon-122001, HARYANA, INDIA

About Aplevant® (dulaglutide)

Aplevant® is Lilly’s dulaglutide once-weekly injection for Type 2 diabetes. Dulaglutide is part of a class of drugs known as a glucagon – like peptide (GLP-1) receptor agonists. It is not insulin and mimics the effects of GLP-1, a natural hormone that helps keep blood sugar levels normal, by helping the body release its own insulin after food intake. Aplevant® (dulaglutide) comes in a ready-to-use pen with a pre-attached, hidden needle that does not require the patient to mix, measure, nor handle the needle. Aplevant® is a once a week treatment.

Aplevant® is a prescription drug that should be taken only on prescription from a registered MD (Internal Medicine) and Endocrinologist. Aplevant® can be used in combination with oral hypoglycemic drugs or existing insulin therapy in addition to diet and exercise.

For further information or queries please contact –

Pooja Thakran
VP – Corporate Communications
Email: poojathakran@lupin.com
Ph: +91-22-66402531 / 8291013225


Arvind Bothra
Head – Investor Relations
Email: arvindbothra@lupin.com
Ph: +91-22-66402137

Lilly India
Corporate Communications
Malvika Mudgal
Email: mudgal_malvika@lilly.com
Ph: +91 9711687289